{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:51:07Z","timestamp":1780692667815,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019621","name":"Ascentage Pharma","doi-asserted-by":"publisher","award":["R01CA266298"],"award-info":[{"award-number":["R01CA266298"]}],"id":[{"id":"10.13039\/100019621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hoc.2025.05.001","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T19:39:56Z","timestamp":1753299596000},"page":"903-915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Triplet Therapies in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"39","author":[{"given":"Jacob D.","family":"Soumerai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2025.05.001_bib1","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.001_bib2","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.001_bib3","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.hoc.2025.05.001_bib4","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.001_bib5","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"Furstenau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.001_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.001_bib7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.001_bib8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.001_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.001_bib10","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","article-title":"Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study","volume":"22","author":"Davids","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.001_bib11","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO-24-02503","article-title":"Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-naive chronic lymphocytic leukemia population enriched for high-risk disease","volume":"43","author":"Davids","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.001_bib12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.2023022730","article-title":"Acalabrutinib, venetoclax, and obinutuzumab in relapsed\/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial","volume":"144","author":"Furstenau","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.001_bib13","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood.2024026685","article-title":"MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial","volume":"145","author":"Furstenau","year":"2025","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.001_bib14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.2023020013","article-title":"Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)\/TP53mut","volume":"142","author":"Huber","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.001_bib15","unstructured":"Jain N, Ferrajoli A, Swaminathan M, et al. Combined pirtobrutinib, venetoclax, and obinutuzumab as first-line treatment of patients with chronic lymphocytic leukemia (CLL). ASH annual meeting; December 9, 2024; San Diego, CA: Blood; 2024."},{"key":"10.1016\/j.hoc.2025.05.001_bib16","unstructured":"Rogers KA, Huang Y, Bhat S, et al. 7-year update on a phase 2 trial of fixedduration obinutuzumab, ibrutinib, and venetoclax for CLL. EHA congress; June 14, 2024; Madrid, Spain: Haematologica; 2024."},{"issue":"31","key":"10.1016\/j.hoc.2025.05.001_bib17","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.20.00491","article-title":"Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naive and relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Rogers","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.05.001_bib18","doi-asserted-by":"crossref","unstructured":"Soumerai J, Dogan A, Seshan V, et al. Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-na\u00efve chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (\u0394MRD400). ASH annual meeting; December 9, 2024; San Diego: Blood; 2024.","DOI":"10.1182\/blood-2024-205697"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.001_bib19","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2025.05.001_bib21","doi-asserted-by":"crossref","unstructured":"Woyach J, Yin J, Brown JR, et al. Results of A041702: a phase 3 study of IVO vs IO for previously untreated older patients with chronic lymphocytic leukemia and impact of COVID-19 ASCO Annual Meeting; May 31, 2023; Chicago, IL: J Clin Oncol; 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.7500"},{"key":"10.1016\/j.hoc.2025.05.001_bib22","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma V.3.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Available at: NCCN.org. Accessed May 1, 2025."},{"issue":"5","key":"10.1016\/j.hoc.2025.05.001_bib23","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/bloodadvances.2024014474","article-title":"Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL","volume":"9","author":"Soumerai","year":"2025","journal-title":"Blood Adv"},{"issue":"31","key":"10.1016\/j.hoc.2025.05.001_bib24","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.001_bib25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.001_bib26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2025.05.001_bib27","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.001_bib28","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for B-Cell Lymphomas V.2.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Available at: NCCN.org. Accessed May 1, 2025."},{"issue":"5","key":"10.1016\/j.hoc.2025.05.001_bib29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.001_bib30","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bjh.17984","article-title":"Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials","volume":"196","author":"Allan","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.001_bib31","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.001_bib32","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.001_bib33","first-page":"121","article-title":"Six-year update of the ELEVATE-TN study on acalabrutinib","volume":"22","author":"Sharman","year":"2024","journal-title":"Clin Adv Hematol Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.001_bib34","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3324\/haematol.2020.259432","article-title":"Zanubrutinib monotherapy for patients with treatment naive chronic lymphocytic leukemia and 17p deletion","volume":"106","author":"Tam","year":"2021","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.hoc.2025.05.001_bib35","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood.2023021959","article-title":"Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL","volume":"143","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.001_bib36","doi-asserted-by":"crossref","unstructured":"Wierda W, Jacobs R, Barr PM, et al. Outcomes in high-risk subgroups after fixedduration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): up to 5.5 years of follow-up in the phase 2 CAPTIVATE study. ASCO Annual Meeting; May 29, 2024; Chicago, IL: J Clin Oncol; 2024.","DOI":"10.1016\/S2152-2650(24)00564-0"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:42:55Z","timestamp":1762314175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0889858825000632"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triplet Therapies in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}